Brief: Gt Biopharma Gtb-1550 Clinical Development Update

GT Biopharma

30/05/2019 12:38

May 30 (Reuters) - GT Biopharma Inc  GTBP.PK :
    * GT BIOPHARMA GTB-1550 CLINICAL DEVELOPMENT UPDATE
    * GT BIOPHARMA INC - DURABLE COMPLETE REMISSION IN PATIENT
CURRENTLY DISEASE-FREE AT 50 MONTHS POST TREATMENT
    * GT BIOPHARMA INC - GREATER THAN 50% OF EVALUABLE PATIENTS
RECEIVING 60 MG/KG DOSE HAD POSITIVE CLINICAL RESPONSE
    * GT BIOPHARMA INC - PLANNING TO PROCEED WITH A PHASE II
CLINICAL
TRIAL FOR GTB-1550

Source text for Eikon:  ID:nPn1KC494a 
Further company coverage:  GTBP.PK 

 (Reuters.Briefs@thomsonreuters.com)